Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly ... in their drug pipeline, particularly the oral GLP-1 drug Orforglipron for diabetes and weight loss, and ...

GLP-1 drugs still lead the way for Eli Lilly Turning to its GLP-1 drugs ... help improve blood glucose levels in adults with type 2 diabetes, but is commonly used off-label for weight loss.